Objective
To identify novel metabolic markers for diabetes development in American Indians.

Research Design and Methods
Using an untargeted high-resolution liquid chromatography–mass spectrometry, we conducted metabolomics analysis of study participants who developed incident diabetes (n = 133) and those who did not (n = 298) from 2,117 normoglycemic American Indians followed for an average of 5.5 years in the Strong Heart Family Study. Relative abundances of metabolites were quantified in baseline fasting plasma of all 431 participants. Prospective association of each metabolite with risk of developing type 2 diabetes (T2D) was examined using logistic regression adjusting for established diabetes risk factors.

Results
Seven metabolites (five known and two unknown) significantly predict the risk of T2D. Notably, one metabolite matching 2-hydroxybiphenyl was significantly associated with an increased risk of diabetes, whereas four metabolites matching PC (22:6/20:4), (3S)-7-hydroxy-2′,3′,4′,5′,8-pentamethoxyisoflavan, or tetrapeptides were significantly associated with decreased risk of diabetes. A multimarker score comprising all seven metabolites significantly improved risk prediction beyond established diabetes risk factors including BMI, fasting glucose, and insulin resistance.

Conclusions
The findings suggest that these newly detected metabolites may represent novel prognostic markers of T2D in American Indians, a group suffering from a disproportionately high rate of T2D.
metabolic pathways implicated in T2D development will not only provide novel insights into disease pathophysiology but also provide instrumental data for risk prediction and for developing effective therapeutic and preventive strategies against diabetes.

Metabolomics is an emerging analytical technology that simultaneously quantifies many metabolites in biofluids. These metabolites represent the end products of cellular metabolism in response to intrinsic and extrinsic stimuli and thus may reflect the metabolic changes at earlier stages of disease. Cross-sectional analyses have reported associations of altered metabolites with obesity (2), insulin resistance (3), prediabetes, and overt T2D (4–7). These changes included acylcarnitines (6,8), amino acids (2,8,9), and different lipid species (5,8,9). Higher plasma levels of branched-chain amino acids (BCAAs) and aromatic amino acids were associated with an increased risk of T2D in the Framingham Offspring study (10). Another study found that increased diacyl-phosphatidylcholines and reduced acyl-alkyl- and lysophosphatidylcholines as well as sphingomyelins were associated with diabetes in a European population (11). More recently, α-hydroxybutyrate and linoleoylglycerophosphocholine were also found to predict the development of dysglycemia and T2D in Europeans (12). These findings derived from European populations, however, may not represent metabolic alterations in other ethnic groups. Moreover, most existing studies used a targeted metabolomics approach by focusing on a subset of preselected metabolites and thus may have limited ability in discovering novel disease-related metabolic changes. The clinical utility of previously detected metabolites in risk prediction was either not reported or was minimal over conventional clinical factors.

The goal of this study is to identify predictive metabolic markers for future risk of T2D in American Indians, a minority group suffering from a disproportionately high rate of T2D. Metabolic profiles of diabetes development were examined in normoglycemic participants using fasting plasma samples collected prior to disease occurrence. The utility of novel metabolic markers in risk prediction beyond established diabetes risk factors was also investigated.

RESEARCH DESIGN AND METHODS

Study Population

Participants included in the current study were selected from the Strong Heart Family Study (SHFS), a family-based prospective study designed to identify genetic factors for cardiovascular disease (CVD), diabetes, and their risk factors in American Indians residing in Arizona, North and South Dakota, and Oklahoma. A detailed description for the study design and methods of the SHFS had been reported previously (13,14). In brief, a total of 3,665 tribal members (aged 14 years and older) from 94 multiplex families (65 three-generation and 29 two-generation families, average family size 38) were recruited and examined in 2001–2003. All living participants were followed and reexamined between 2006 and 2009. The SHFS protocol was approved by the institutional review boards from the Indian Health Service and the participating study centers. All participants gave informed consent.

According to the American Diabetes Association 2003 criteria (15), diabetes was defined as fasting plasma glucose ≥7.0 mmol/L or hypoglycemic medica tions. Impaired fasting glucose was defined as a fasting glucose of 6.1–6.9 mmol/L and no hypoglycemic medications, and normal fasting glucose (NFG) was defined as fasting glucose <6.1 mmol/L. Incident cases of T2D were defined as normal fasting glucose at baseline (2001–2003) and development of new T2D by the end of follow-up (2006–2009).

Participants included in the current analysis have to meet the following criteria: 1) attended clinical examinations at both baseline (2001–2003) and follow-up (2006–2009), 2) had NFG at baseline, 3) were free of overt CVD and hypoglycemic medications at baseline, and 4) had available fasting plasma sample at baseline for the proposed metabolomic analysis. Participants with missing information for fasting glucose or antidiabetes medication at either baseline or follow-up were also excluded from the current analysis.

A total of 2,324 participants free of overt CVD at baseline attended both clinical visits and had available fasting plasma samples for the proposed analysis. Of these, 2,117 normoglycemic participants met all of the criteria listed above. After an average 5.5 years of follow-up, 197 participants (9.3%) developed incident T2D. Among those who did not develop T2D (n = 1,920), 159 participants (7.5%) progressed to impaired fasting glucose, whereas the other individuals (n = 1,761) remained with stable NFG by the end of follow-up. The current metabolomics analysis measured metabolite levels in fasting plasma of 431 participants, including 133 incident cases randomly selected from participants who developed new T2D (n = 197) and 298 control subjects randomly selected from those who did not develop T2D (n = 1,920). Supplementary Table 1 shows the comparison of baseline clinical characteristics between participants who were selected and those not selected.

Assessments of Diabetes Risk Factors

Fasting plasma glucose, insulin, lipids, lipoproteins, and inflammatory biomarkers were measured by standard laboratory methods (14,16). BMI was calculated as body weight in kilograms divided by the square of height in meters. Hypertension was defined as blood pressure levels ≥140/90 mmHg or use of antihypertensive medications. Insulin resistance was assessed using HOMA according to the following formula: HOMA of insulin resistance (HOMA-IR) = fasting glucose (mg/dL) × insulin (µU/mL)/405 (17). Renal function was assessed using the estimated glomerular filtration rate (eGFR) calculated by the MDRD equation (18). For cigarette smoking, subjects were classified as current smokers, former smokers, and nonsmokers. Alcohol consumption was determined by self-reported history of alcohol intake, the type of alcoholic beverages consumed, frequency of alcohol consumption, and average quantity consumed per day and per week. Participants are classified as current drinkers, former drinkers, and never drinkers. Dietary intake was assessed using the block food frequency questionnaire (19).

Metabolic Profiling by High-Resolution Liquid Chromatography–Mass Spectrometry

Relative abundance of fasting plasma metabolites was determined using high-resolution liquid chromatography–mass spectrometry (LC-MS). Detailed laboratory protocols have previously been described (20,21). Briefly, 65 µL plasma
To identify metabolic predictors and to estimate their effects on the risk of developing T2D, we constructed a Cox proportional hazards frailty model, in which time to event was the dependent variable and the level of each metabolite was the independent variable. The frailty model was used here to account for the relatedness among family members. The proportional hazards assumption was tested using the Schoenfeld residuals, and it shows that the proportionality assumption holds in our data. For estimation of metabolic effects that are independent of traditional risk factors, the Cox frailty model was adjusted for age, sex, site, BMI, eGFR, HDL, triglycerides, fasting glucose, and insulin resistance (assessed by HOMA-IR) at baseline. Given the potential high correlations among detected metabolites, we used the q value method to adjust for multiple testing (30), and a q value <0.05 was considered statistically significant.

To examine the combined effects of metabolites on diabetes risk, we constructed a multimarker metabolites score based on metabolites that are significantly predictive of diabetes risk by fitting a model according to the following formula: \( \beta_1 X_1 + \beta_2 X_2 + \beta_3 X_3 \), where \( X_i \) denotes the z score of the i-th metabolite and \( \beta_i \) denotes the regression coefficient from the logistic regression model containing the indicated metabolites. The joint predictive ability of metabolites was assessed using logistic regression by including all clinical risk factors (age, sex, study site, BMI, eGFR, HDL, triglycerides, fasting glucose, and HOMA-IR) plus the multimarker metabolites score compared with the model including clinical risk factors only. We calculated the area under the receiver operating characteristic curve (AUC), the net reclassification improvement (NRI), and the integrated discrimination improvement (IDI) to assess the incremental value of the metabolic markers for risk prediction beyond classical risk factors. Because our analysis was based on a regression model with no cross-validation or external validation, it is likely that our model could be overfitted. To avoid or minimize bias due to overfitting, we conducted a bootstrap estimation (1,000 reps) for coefficients by SAS to obtain bias-corrected estimates of metabolites on risk of diabetes.

To identify metabolic profiles associated with risk of diabetes, we conducted sparse partial least-squares discriminant analysis (sPLS-DA) using the computer package mixOmics implemented in R. The sPLS-DA is a supervised, multivariate technique to determine metabolic groups associated with disease risk. The sPLS-DA analysis included only metabolites showing significant associations with risk of diabetes. For ease of visualization, we presented a Manhattan plot (\( -\log_{10} P \) vs. metabolic feature) to show the significance of individual metabolites according to status of incident cases at follow-up using raw P values obtained from multivariate logistic regression analysis (false discovery rate at \( q = 0.05 \) with a horizontal line).

RESULTS

Table 1 presents the characteristics of the study participants at baseline (2001–2003) according to diabetes status at the end of follow-up (2006–2009). The average follow-up period was 5.5 years. Compared with participants who did not develop T2D, those who developed incident T2D had higher levels of BMI, triglycerides, fasting glucose, fasting insulin, and insulin resistance (HOMA-IR) but lower level of HDL at baseline. We also compared participants who were selected (n = 431) versus those not selected (n = 1,686) for this study. It shows that, except for BMI and eGFR, selected participants were not appreciably different from those not selected (Supplementary Table 1).

Our untargeted high-resolution LC-MS detected 11,628 distinct ions (m/z) with CV ≤10%, of which 2,093 m/z features matched known compounds in available metabolomics databases. Among all 11,628 features, altered levels of seven metabolites (five matching known metabolites and two unknown) were significantly associated with risk of diabetes after adjustment for clinical factors and multiple testing. Specially, a metabolite matching 2-hydroxybiphenyl (2HBP) and an unknown chemical (m/z ratio 1,178.804 [named X-1178]) were significantly associated with an increased risk of diabetes, whereas five metabolites matching phosphatidylycholine (PC 22:6/20:4), (3S)-7-hydroxy-2’3’,4’,5’,8-pentamethoxyflavone (HPMF), two tetrapeptides (Met-Glu-Ile-Arg [MEIR] and...
Leu-Asp-Tyr-Arg [LDYR]), and an unknown metabolite (m/z ratio 490.816 [named X-490]) were significantly associated with a decreased risk of diabetes. These associations are independent of clinical factors including fasting glucose and insulin resistance. Per-SD increase in the log-transformed levels of matching 2HBP and X-1178 was associated with 32–42% decreased risk of T2D. In the multivariate model categorizing metabolites as tertiles, participants in the top tertile of 2HBP and X-1178 had a hazard ratio (HR) of 2.80 (95% CI 1.19–6.60) and 2.87 (95% CI 1.08–7.60) for developing incident T2D, respectively, compared with those in the lowest tertile. In contrast, participants in the top tertile of PC (22:6/20:4), HPMF, tetrapeptides, and X-490 had an HR of 0.45 (95% CI 0.21–0.97), 0.38 (95% CI 0.18–0.80), 0.44 (95% CI 0.20–0.96), 0.37 (95% CI 0.16–0.87), and 0.46 (95% CI 0.21–0.97) for developing T2D, respectively, compared with those in the lowest tertile of these metabolites.

To estimate the joint effects of metabolites on risk of diabetes development, we calculated HRs across tertiles of the summed metabolites of 2HBP and X-1178. Participants in the top tertile of these metabolites. In the multivariate association of baseline fasting plasma metabolites with risk of developing incident T2D, respectively, compared with those in the lowest tertile of these metabolites.

| Table 1—Characteristics of the study participants at baseline (2001–2003) |
|-----------------------------------------------|
| Participants who developed T2D | Participants who did not develop T2D | \( p^* \) |
| n | 133 | 298 |
| Age, years | 35.45 ± 12.2 | 33.36 ± 13.88 | 0.1208 |
| Female sex, % | 67.67 | 63.42 | 0.3885 |
| BMI, kg/m² | 36.74 ± 7.96 | 31.11 ± 8.00 | <0.0001 |
| Current smoker, % | 33.83 | 36.58 | 0.7266 |
| Current drinker, % | 63.16 | 68.79 | 0.5034 |
| Systolic blood pressure, mmHg | 120.88 ± 15.34 | 118.87 ± 12.96 | 0.1868 |
| Diastolic blood pressure, mmHg | 77.39 ± 11.80 | 75.63 ± 10.46 | 0.1222 |
| HDL, mg/dL | 47.52 ± 14.41 | 52.44 ± 14.63 | 0.0016 |
| LDL, mg/dL | 100.92 ± 29.32 | 96.06 ± 28.57 | 0.1062 |
| Total triglyceride, mg/dL | 167.20 ± 99.12 | 132.16 ± 65.47 | <0.0001 |
| Total cholesterol, mg/dL | 180.70 ± 34.16 | 174.75 ± 33.48 | 0.0923 |
| eGFR, ml/min/1.73 m² | 104.56 ± 21.41 | 105.18 ± 24.84 | 0.7917 |
| Fasting glucose, mg/dL | 94.30 ± 7.81 | 89.55 ± 6.41 | <0.0001 |
| Fasting insulin, μU/mL | 20.52 ± 13.08 | 14.14 ± 11.47 | 0.0001 |
| Insulin resistance (HOMA-IR) | 4.80 ± 3.07 | 3.15 ± 2.60 | <0.0001 |
| Total caloric intake, kcal/day | 2,887.59 | 2,117.20 | 0.7409 |
| Total dietary protein, g/day | 97.51 | 94.99 | 0.7768 |
| Total dietary fat, g/day | 126.39 | 123.71 | 0.8017 |

Data are mean ± SD unless otherwise indicated. *Adjusting for family relatedness by generalized estimating equation.

To investigate whether these detected metabolites improve risk prediction, we added the weighted multimarker score comprising all seven metabolites to the fully adjusted statistical model. Results show that addition of the multimarker score resulted in significant improvement in the log-transformed levels of matching 2HBP with fasting insulin or insulin resistance. Per-SD increase in the log-transformed levels of matching 2HBP and X-1178 was associated with 32–42% decreased risk of T2D. In the multivariate model categorizing metabolites as tertiles, participants in the top tertile of 2HBP and X-1178 had a hazard ratio (HR) of 2.80 (95% CI 1.19–6.60) and 2.87 (95% CI 1.08–7.60) for developing incident T2D, respectively, compared with those in the lowest tertile of these metabolites.

| Table 2—Multivariate association of baseline fasting plasma metabolites with risk of developing T2D in American Indians by Cox proportional hazards frailty model |
|-----------------------------------------------|
| Matching metabolites | Metabolite as continuous variable* | Metabolite as categorical variable* |
| Protective metabolites | PC (22:6/20:4) | 0.68 (0.52–0.88) | 0.45 (0.21–0.97) |
| | HPMF | 0.58 (0.43–0.79) | 0.38 (0.18–0.80) |
| | MEIR | 0.61 (0.47–0.78) | 0.44 (0.20–0.96) |
| | LDYR | 0.63 (0.47–0.85) | 0.37 (0.16–0.87) |
| | X-490 | 0.65 (0.50–0.84) | 0.46 (0.21–0.97) |
| Combined protective effects | 0.43 (0.31–0.59) | 0.23 (0.10–0.51) |
| Risk metabolites | 2HBP | 1.80 (1.26–2.57) | 2.80 (1.19–6.60) |
| | X-1178 | 1.89 (1.29–2.77) | 2.87 (1.08–7.60) |
| Combined risk effects | 2.56 (1.71–3.84) | 6.89 (2.63–18.08) |

Data are HR (95% CI). †Adjusted for age, sex, site, BMI, eGFR, HDL, triglycerides, fasting glucose, and HOMA-IR. *HR per SD change in log-transformed metabolite level. ‡Tertile 3 vs. tertile 1.
unknown compound (X-490) were not correlated with any of the known risk factors for diabetes.

To identify metabolic profiles associated with risk of diabetes development, we conducted sPLS-DA using the seven metabolites that were significantly predictive of disease risk. Fig. 2 demonstrates that participants who developed T2D and those who did not were separated into two distinct groups, suggesting that these metabolites could be used as discriminatory markers for T2D risk stratification. This observation is consistent with our results obtained by risk prediction analyses (i.e., AUC, NRI, and IDI). Additional adjustments for dietary intake of fat, protein, and caloric intake did not attenuate the observed associations (data not shown).

CONCLUSIONS

In this prospective investigation using an untargeted high-resolution metabolomic approach, we found that seven metabolites independently predict future onset of T2D in American Indians, a group with a high rate of diabetes. Of the five chemicals matching known metabolites, two were lipids in the classes of glycerophosphocholine (PC) and flavonoid. It should be noted that there are many isobaric lipids, so the precise structural identifications will require additional research. The observed association withstood adjustments for multiple clinical indicators including age, sex, study site, BMI, eGFR, HDL, triglycerides, fasting glucose, and insulin resistance (HOMA-IR). The combination of these metabolites significantly improves risk prediction beyond established diabetes risk factors. These metabolites have not been reported in previous studies of European individuals or other ethnic groups and thus should represent putative prognostic markers of diabetes specific to American Indians.

We found that a metabolite matching 2HBP was associated with 80% increased risk of developing T2D independent of classical risk factors. The mechanism by which this metabolite affects diabetes risk is unclear. However,
2HBP is known to be an environmental toxin that is widely used as industrial antimicrobials, agricultural fungicide, and disinfectants. 2HBP was reported to be mutagenic in human cells (31) and carcinogenic in animal models (32,33). In addition, hydroxybiphenyl chemicals can be degraded by bacteria through the biphenyl catabolic pathway (34). It is thus plausible to hypothesize that, apart from the possible direct toxic effects of 2HBP on pancreas or peripheral tissues, 2HBP may also negatively affect diabetes through a yet unknown host-gut microbiota mechanism.

Glycerophosphocholines are important structural components of plasma lipoproteins and cell membranes with diverse biological functions. In this study, we found that elevated plasma level of matching PC (22:6/20:4) was associated with 37% reduced risk of T2D in our study population. This is in agreement with a previous study demonstrating lower plasma or serum levels of PC species in diabetic patients than in control subjects (5). Moreover, reduced levels of multiple acyl-glycerophospholine species were highly correlated with insulin resistance as measured by the euglycemic clamp (35), lending further support for a potential role of PCs in diabetes etiology. In the current investigation, another metabolite matching known (35)-7-hydroxy-2',3',4',5',8-pentamethoxyisoflavon (named HPMF) was also significantly predictive of a decreased risk of diabetes. This metabolite belongs to the class of flavonoids that are known to have a wide range of biological and pharmacological activities. Dietary flavonoid intakes have been associated with reduced risk of T2D in both human (36–38) and animal studies (39). In support of these findings, participants with a higher plasma level (top tertile) of HPMF exhibited over 60% reduced risk of T2D compared with those with a lower level (bottom tertile) in our analysis. While the precise mechanism underlying this association awaits further investigation, it is possible that HPMF may decrease diabetes risk through its potential antioxidant properties (40). It is also likely that HPMF may exert beneficial effects on energy balance and lipid metabolism (41) or anti-inflammatory effects through the nuclear factor-κB or the AMPK signaling pathways, which play a central role in the regulation of glucose and lipid metabolism (42,43). In addition, flavonoids have been shown to have anti-diabetes effects through enhanced pancreatic β-cell function in animal experiments (44). The favorable effect of this flavonoid chemical has not been previously reported. Its biological properties should be investigated in future research.

In addition to the altered profiles of PC and flavonoid, elevated levels of two metabolites matching tetrapeptides (MEIR and LDYR) were associated with ~40% reduced risk of diabetes. Although the mechanisms linking these peptides to diabetes remain to be determined, peptides are known to be essential in regulating lipid metabolism in key insulin-target tissues and in maintaining energy homeostasis and insulin sensitivity. They may also function as potent peptide hormones regulating glucose metabolism in diabetes (45). In addition to the five known matching metabolites, two unknown compounds were also significantly predictive of diabetes development. These unknown chemicals might be not new but merely not yet identified. The structure and function of these unannotated chemicals should be examined in future research.

Previous evidence has linked raised circulating levels of BCAAs with insulin resistance (2,46,47) or diabetes (10,47). Our study, however, did not find a significant association of BCAAs with risk of T2D development. This lack of replication may not necessarily represent true negative findings because our analysis accounted for multiple testing of >11,000 m/z features with a stringent criterion, which could result in inappropriate exclusion for a large number of metabolites (false negatives). The discrepancy could also represent genuine differences between American Indians and other ethnic groups included in previous studies because the unique characteristics of American Indians, e.g., genetic background and lifestyle, could potentially lead to population-specific metabolic signatures. Future large-scale metabolomics studies should address this discrepancy.

In search of the origin of the interindividual variation, we calculated partial correlations of metabolite relative abundance with standard risk indicators of diabetes, expecting that, for example, higher BMI or fasting glucose should correspond with higher levels of risk metabolites or lower levels of protective metabolites. However, in our study cohort, most of the detected matching metabolites were not correlated with classical risk factors, such as BMI, fasting glucose, and insulin resistance, but the combination of these metabolites significantly improved risk prediction beyond standard risk factors. This is important because the fundamental task of risk prediction is to identify predictive markers that are sufficiently uncorrelated with established risk factors so that they can be used to improve risk prediction over and above conventional clinical factors. These newly detected metabolic markers will provide valuable information regarding the pathophysiology of diabetes development and also potential therapeutic targets for novel treatment options.

Our study has several limitations. First, although our high-resolution LC-MS detected >1,000 distinct features, it should be noted that only 18% of the compounds detected had a match in the current metabolomics database. These compounds were unable to be pursued owing to the large number of possible isomers and a lack of available standards. However, these currently unannotated metabolites may represent dietary, microbiome-related, or environmental chemicals associated with diabetes. With the advancement of metabolomic research, we expect that the majority of these unidentifiable chemicals will ultimately be annotated and their associations with disease will be determined. Additionally, many m/z features matched to therapeutic drugs and nutritional supplements, but owing to their wide use by diabetic patients, we were unable to evaluate their contributions to the altered metabolic profiles. Second, although highly correlated, relative abundances but not absolute concentrations were used as a surrogate for plasma metabolite levels. Third, although we were able to control many of the known risk factors, the possibility of potential confounding by other factors such as diet and gut microbiota cannot be entirely excluded. Fourth, participants in the current study are young to middle-aged American Indians who may have a high propensity for the development of T2D; therefore, generalization of our findings to other populations should be approached cautiously. However, given the rising tide of T2D
New Metabolic Markers for Diabetes Risk

Diabetes Care

References

1. Defronzo RA. Banting Lecture. From the tri-
numvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773–795

2. Newgard CB, An J, Bain JR, et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean hu-
 mans and contributes to insulin resistance. Cell Metab 2009;9:311–326

3. Wurtz P, Mäkinen VP, Soininen P, et al. Metabolic signatures of insulin resistance in 7,096 young adults. Diabetes 2012;61:1372–1380

4. Wopereis S, Rubingh CM, van Erk MJ, et al. Metabolic profiling of the response to an oral glucose tolerance test detects subtle metabolic changes. PLoS ONE 2009;4:e4525

5. Suhré K, Mesinger C, Döring A, et al. Meta-
bolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS ONE 2010;5:e11953

6. Adams SH, Hoppel CL, Lok KH, et al. Plasma acylcarnitine profiles suggest incomplete long-
chain fatty acid beta-oxidation and altered tri-
 carbocyclic acid cycle activity in type 2 diabetic African-American women. J Nutr 2009;139: 1073–1081

7. Fiehn O, Garvey WT, Newman JW, Lok KH, Hoppel CL, Adams SH. Plasma metabolomic profiles reflective of glucose homeostasis in non-diabetic and type 2 diabetic obese African-
American women. PLoS ONE 2010;5:e15234

8. Wang-Sattler R, Yu Z, Herder C, et al. Novel biomarkers for pre-diabetes identified by me-
tabolomics. Mol Syst Biol 2012;8:615

9. Menni C, Fauman E, Erte I, et al. Biomarkers for type 2 diabetes and impaired fasting glucose using a nontargeted metabolomics approach. Diabetes 2013;62:4270–4276

10. Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes. Nat Med 2011;17:448–453

11. Floegel A, Stefan N, Yu Z, et al. Identifi-
cation of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes 2013;62:639–648

12. Ferrannini E, Natali A, Camasa S, et al. Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physi-
ological significance. Diabetes 2013;62:1730–1737

13. North KE, Howard BV, Welty TK, et al. Genetic and environmental contributions to cardiovascular disease risk in American Indians: the strong heart family study. Am J Epidemiol 2003;157:303–314

14. Lee ET, Welty TK, Fabisz R, et al. The Strong Heart Study. A study of cardiovascular disease in American Indians: design and meth-
ods. Am J Epidemiol 1990;132:1141–1155

15. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003;26(Suppl. 1):55–520

16. Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol 1957;17:237–246 [in German]

17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-
cell function from fasting plasma glucose and in-
sulin concentrations in man. Diabetologia 1985; 28:412–419

18. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from se-
rum creatinine: a new prediction equation. Ann Intern Med 1999;130:461–470

19. Willett W; Food frequency methods. In Nutritional Epidemiology. 2nd ed. New York, Oxford University Press, 1998, p. 74–91

20. Osborn MP, Park Y, Parks MB, et al. Metabolome-wide association study of neovas-
cular age-related macular degeneration. PLoS ONE 2013;8:e72737

21. Roede JR, Uppal K, Park Y, et al. Serum metabolomics of slow vs. rapid motor progres-
sion Parkinson’s disease: a pilot study. PLoS ONE 2013;8:e77629

22. Yu T, Park Y, Johnson JM, Jones DP. apLCMS—adaptive processing of high-resolution LC/MS data. Bioinformatics 2009;25:1930–1936

23. Yu T, Park Y, Li S, Jones DP. Hybrid feature detection and information accumulation using high-resolution LC-MS metabolomics data. J Proteome Res 2013;12:1419–1427

24. Uppal K, Soltow QA, Strobel FH, et al. eMSanalyzer: automated pipeline for improved feature detection and downstream analysis of large-scale, non-targeted metabolomics data. BMC Bioinformatics 2013;14:15

25. Smith CA, O’Maille G, Want EJ, et al. METLIN: a metabolite mass spectral database. Ther Drug Monit 2005;27:747–751

26. Wishart DS, Jewison T, Guo AC, et al. HMDB 3.0—The Human Metabolome Database in 2013. Nucleic Acids Res 2013;41:D801–D807

27. Sud M, Fahy E, Cotter D, et al. LMSD: LIPID MAPS structure database. Nucleic Acids Res 2007;35:D527–D532

28. Hughes G, Cruickshank-Quinn C, Richardson R, et al. MSPrep—summarization, normalization and diagnostics for processing of mass spectrometry-based metabolomic data. Bioinformatics 2014;30: 133–134

29. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data us-
ing empirical Bayes methods. Biostatistics 2007; 8:118–127

30. Storey JD. A direct approach to false dis-
cover rates. J R Stat Soc Series B Stat Methodol 2002;64:187–205

31. Suzuki H, Suzuki N, Sasaki M, Hiraga K. Orthophenylphenol mutagenicity in a human cell strain. Mutat Res 1985;156:123–127

32. Brusick D. Analysis of genotoxicity and the car-
icogenic mode of action for ortho-phenolphen. Environ Mol Mutagen 2005;45:460–491

33. Hagiwara A, Shibata M, Hirose M, Fukushima S, Ito N. Long-term toxicity and carcinogenic mode of action for ortho-phenylphenol. J Ind Microbiol 1991;6:77–88
35. Gall WE, Beebe K, Lawton KA, et al.; RISC Study Group. alpha-Hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS ONE 2010;5:e10883
36. van Dam RM, Naidoo N, Landberg R. Dietary flavonoids and the development of type 2 diabetes and cardiovascular diseases: review of recent findings. Curr Opin Lipidol 2013;24:25–33
37. Wedick NM, Pan A, Cassidy A, et al. Dietary flavonoid intakes and risk of type 2 diabetes in US men and women. Am J Clin Nutr 2012;95:925–933
38. Zamora-Ros R, Forouhi NG, Sharp SJ, et al. The association between dietary flavonoid and lignan intakes and incident type 2 diabetes in European populations: the EPIC-InterAct study. Diabetes Care 2013;36:3961–3970
39. Chen YK, Cheung C, Reuhl KR, et al. Effects of green tea polyphenol (−)-epigallocatechin-3-gallate on newly developed high-fat/Western-style diet-induced obesity and metabolic syndrome in mice. J Agric Food Chem 2011;59:11862–11871
40. Lotito SB, Zhang WJ, Yang CS, Crozier A, Frei B. Metabolic conversion of dietary flavonoids alters their anti-inflammatory and antioxidant properties. Free Radic Biol Med 2011;51:454–463
41. Friedrich M, Petzke KJ, Raederstorff D, Wolfram S, Klaus S. Acute effects of epigallocatechin gallate from green tea on oxidation and tissue incorporation of dietary lipids in mice fed a high-fat diet. Int J Obes (Lond) 2012;36:735–743
42. Salminen A, Hyttinen JM, Kaarniranta K. AMP-activated protein kinase inhibits NF-κB signaling and inflammation: impact on health-span and lifespan. J Mol Med (Berl) 2011;89:667–676
43. Leiherer A, Mündlein A, Drexel H. Phytochemicals and their impact on adipose tissue inflammation and diabetes. Vascul Pharmacol 2013;58:3–20
44. Ortsäter H, Granqvist N, Wolfram S, Kuehn N, Sjöholm A. Diet supplementation with green tea extract epigallocatechin gallate prevents progression to glucose intolerance in db/db mice. Nutr Metab (Lond) 2012;9:11
45. Todd JF, Bloom SR. Incretins and other peptides in the treatment of diabetes. Diabet Med 2007;24:223–232
46. Huffman KM, Shah SH, Stevens RD, et al. Relationships between circulating metabolic intermediates and insulin action in overweight to obese, inactive men and women. Diabetes Care 2009;32:1678–1683
47. Stancakova A, Civelek M, Saleem NK, et al. Hyperglycemia and a common variant of GCKR are associated with the levels of eight amino acids in 9,369 Finnish men. Diabetes 2012;61:1895–1902